Hatchtech raises $6.3M for DeOvo™ head lice phase 2b clinical trial

26/10/2010 | Press Releases

Venture-backed pharmaceutical company Hatchtech Pty Ltd has concluded a $6.3 million capital raising to conduct a Phase 2b clinical trial for its very promising head lice treatment.